| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802310801036 | 231080103 | LOXITAN TAB 7,5MG/TAB BTx20 (BLIST 2x10) | 2.49 | 2.61 | 3.59 |
| 05/2018 | 2802310802040 | 231080204 | LOXITAN TAB 15MG/TAB BTx30 (BLIST 3x10) | 2.98 | 3.13 | 4.31 |
| 05/2018 | 2802310805034 | 231080503 | LOXITAN INJ.SOL 15MG/1.5ML AMP BTx5AMPSx1,5 ML | 2.22 | 2.33 | 3.21 |
For symptomatic treatment of arthritis and osteoarthritis.
Anti-inflammatory effects of meloxicam are believed to be due to inhibition of prostaglandin synthetase (cylooxygenase), leading to the inhibition of prostaglandin synthesis. As prostaglandins sensitize pain receptors, inhibition of their synthesis may be associated with the analgesic and antipyretic effects of meloxicam.
LD<sub>50</sub>, Acute: 84 mg/kg (Rat); Oral 470 mg/kg (Mouse); Oral 320 mg/kg (Rabbit)
Absolute bioavailability = 89%
15-20 hours
Meloxicam is almost completely metabolized to four pharmacologically inactive metabolites. Meloxicam excretion is predominantly in the form of metabolites, and occurs to equal extents in the urine and feces. Only traces of the unchanged parent compound are excreted in the urine (0.2%) and feces (1.6%). The extent of the urinary excretion was confirmed for unlabeled multiple 7.5 mg doses: 0.5%, 6% and 13% of the dose were found in urine in the form of meloxicam, and the 5'-hydroxymethyl and 5'-carboxy metabolites, respectively.
* 10 L
* 8.8 mL/min [Healthy Male Adults (Fed) oral 7.5 mg tablets] * 9.9 mL/min [Eldery Male (Fed) oral 15 mg capsules] * 5.1 mL/min [Eldery Female (Fed) oral 15 mg capsules] * 19 mL/min [Renal Failure (Fasted) oral 15 mg capsules] * 11 mL/min [Hepatic Insufficiency (Fasted) oral 15 mg capsules]